Heron Therapeutics | HRTX - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amarin USD -852K 7.26M 2025-12
ANI Pharmaceuticals USD 31.48M 18.04M 2025-12
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Eisai JPY -7.94B 29.94B 2026-03
Esperion Therapeutics USD 63.67M 95M 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -162.1M 164.84M 2026-03
Ligand Pharmaceuticals USD 56.78M 84.36M 2025-12
Merck USD 3.42B 3.32B 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Omeros USD -65.12M 21.27M 2024-06
Pacira USD 571K 8.95M 2025-12
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Veracyte USD 29.97M 10.66M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03